Months earlier, the agency released a report alleging the companies drove up the costs of some medications, including insulin.

The Federal Trade Commission on Friday filed a lawsuit over insulin prices against the three largest pharmaceutical middlemen that negotiate prescription drug prices, arguing that the companies artificially inflate the costs of the lifesaving diabetes drug for patients.

Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.